May-17-22 01:49PM | |
09:10AM | |
08:00AM | |
07:45AM | |
May-12-22 08:00AM | |
May-11-22 08:51AM | |
May-10-22 03:10PM | |
08:00AM | |
May-06-22 10:30PM | |
May-05-22 04:35PM | |
May-04-22 11:07AM | |
May-03-22 04:58PM | |
04:07PM | Investor's Business Daily |
11:00AM | |
10:36AM | |
08:59AM | |
07:42AM | |
07:31AM | |
07:11AM | |
07:00AM | |
May-02-22 03:55PM | |
08:00AM | |
Apr-28-22 05:21AM | |
Apr-26-22 06:42PM | |
Apr-25-22 04:11PM | |
02:25PM | |
09:00AM | |
Apr-21-22 09:05AM | |
Apr-20-22 11:14AM | |
06:17AM | |
Apr-19-22 05:15PM | |
Apr-05-22 02:55PM | |
12:03PM | Investor's Business Daily |
07:34AM | |
Apr-04-22 04:05PM | |
10:55AM | |
06:00AM | |
Apr-01-22 08:00AM | |
Mar-30-22 12:04PM | The Wall Street Journal +6.47% |
11:26AM | |
10:18AM | |
09:38AM | |
09:16AM | |
09:09AM | |
Mar-26-22 07:31AM | |
Mar-25-22 02:18PM | |
04:10AM | |
Mar-22-22 12:16PM | |
06:00AM | American City Business Journals |
Mar-21-22 04:01PM | |
03:36PM | |
02:55PM | |
Mar-17-22 02:19PM | |
Mar-14-22 06:00AM | |
Mar-11-22 11:09AM | |
Mar-07-22 08:00AM | |
Mar-02-22 07:33AM | |
Feb-28-22 06:06AM | |
Feb-16-22 06:20PM | |
Feb-14-22 05:11PM | |
Feb-10-22 11:43AM | |
03:00AM | |
Feb-09-22 04:11PM | Investor's Business Daily +8.44% |
08:02AM | |
07:40AM | |
07:19AM | |
Feb-08-22 03:22PM | |
Feb-07-22 02:16PM | |
10:35AM | |
10:12AM | |
Feb-03-22 05:33PM | |
Feb-01-22 08:00AM | |
Jan-31-22 10:30AM | |
Jan-24-22 09:30AM | |
Jan-20-22 09:06AM | |
Jan-19-22 05:36AM | |
Jan-18-22 04:24PM | |
04:22PM | |
03:50PM | |
08:00AM | |
Jan-17-22 12:05PM | |
Jan-14-22 12:22PM | |
Jan-04-22 01:35PM | |
Jan-03-22 06:22AM | |
05:06AM | |
Dec-30-21 05:20PM | The Wall Street Journal -6.29% |
04:38PM | |
01:44PM | |
01:29PM | |
01:27PM | |
12:04PM | |
12:00PM | |
05:51AM | |
04:52AM | |
Dec-29-21 09:21AM | |
07:50AM | |
Dec-22-21 04:30PM | |
Dec-16-21 02:38PM | |
09:31AM | |
08:31AM | |
|
|
|
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell S.A. to develop mdc-IRM, a risperidone extended-release injectable suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Fridriksdottir Hafrun | Executive VP, Global R&D | May 17 | Sale | 8.22 | 130,000 | 1,068,067 | 1,387 | May 19 07:31 AM | Dethlefs Sven | EVP, North America Commercial | Mar 07 | Sale | 7.37 | 6,993 | 51,515 | 165,381 | Mar 08 04:04 PM | Daniell Richard | Exec. VP, European Commercial | Mar 07 | Sale | 7.37 | 22,576 | 166,311 | 43,182 | Mar 08 04:03 PM | Drape Eric | Executive VP Global Operations | Mar 07 | Sale | 7.37 | 11,334 | 83,494 | 78,072 | Mar 08 04:05 PM | Fridriksdottir Hafrun | Executive VP, Global R&D | Mar 07 | Sale | 7.37 | 8,941 | 65,866 | 126,087 | Mar 08 04:07 PM | Stark David Matthew | Exec. VP Chief Legal Officer | Mar 07 | Sale | 7.37 | 9,057 | 66,720 | 61,137 | Mar 08 04:13 PM | Stark David Matthew | Exec. VP Chief Legal Officer | Mar 04 | Sale | 7.48 | 23,254 | 173,998 | 42,311 | Mar 08 04:13 PM | Fridriksdottir Hafrun | Executive VP, Global R&D | Mar 04 | Sale | 7.48 | 24,638 | 184,354 | 98,977 | Mar 08 04:07 PM | Drape Eric | Executive VP Global Operations | Mar 04 | Sale | 7.48 | 23,458 | 175,524 | 61,191 | Mar 08 04:05 PM | Daniell Richard | Exec. VP, European Commercial | Mar 04 | Sale | 7.48 | 36,376 | 272,183 | 20,280 | Mar 08 04:03 PM | Dethlefs Sven | EVP, North America Commercial | Mar 04 | Sale | 7.48 | 3,904 | 29,212 | 147,422 | Mar 08 04:04 PM | Stark David Matthew | Exec. VP Chief Legal Officer | Feb 28 | Sale | 8.14 | 6,452 | 52,533 | 21,380 | Mar 02 07:54 AM | Shani Eli | EVP,Global Marketing&Portfolio | Feb 28 | Sale | 8.14 | 5,311 | 43,243 | 9,091 | Mar 02 07:53 AM | Fridriksdottir Hafrun | Executive VP, Global R&D | Feb 28 | Sale | 8.14 | 7,590 | 61,799 | 65,509 | Mar 02 07:47 AM | Drape Eric | Executive VP Global Operations | Feb 28 | Sale | 8.14 | 9,797 | 79,769 | 45,830 | Mar 02 07:45 AM | Dethlefs Sven | EVP, North America Commercial | Feb 28 | Sale | 8.14 | 4,862 | 39,587 | 99,457 | Mar 02 07:43 AM | Daniell Richard | Exec. VP, European Commercial | Feb 28 | Sale | 8.14 | 20,598 | 167,713 | 20,280 | Mar 02 07:41 AM | Stark David Matthew | Exec. VP Chief Legal Officer | Feb 09 | Sale | 9.06 | 6,110 | 55,358 | 9,402 | Feb 10 04:13 PM | Fridriksdottir Hafrun | Executive VP, Global R&D | Feb 09 | Sale | 9.06 | 6,116 | 55,412 | 51,417 | Feb 10 04:09 PM | Drape Eric | Executive VP Global Operations | Feb 09 | Sale | 9.06 | 3,583 | 32,464 | 36,113 | Feb 10 04:08 PM | Dethlefs Sven | EVP, North America Commercial | Feb 09 | Sale | 9.06 | 4,138 | 37,491 | 86,973 | Feb 10 04:06 PM | Daniell Richard | Exec. VP, European Commercial | Feb 09 | Sale | 9.06 | 13,135 | 119,010 | 20,280 | Feb 10 04:05 PM | Fridriksdottir Hafrun | Executive VP, Global R&D | Aug 10 | Sale | 9.95 | 50,860 | 506,021 | 41,412 | Aug 12 04:04 PM | Drape Eric | Executive VP Global Operations | May 21 | Sale | 11.01 | 40,000 | 440,320 | 33,128 | May 25 08:41 AM |
|